公开(公告)号：AU2010216152A1

公开(公告)日：2011-08-18

申请号：AU2010216152

申请日：2010-02-17

Applicant: UCB PHARMA SA

Inventor： GRIFFITHS LAWSON ALASTAIR DAVID ,  MALCOLM NESBITT ANDREW ,  GEORGE POPPLEWELL ANDREW ,  GRAHAM SHAW STEPHEN ,  DIANA SHPEKTOR ,  YI ZHANG

IPC: C07K2/00 ,  A61K39/395 ,  A61P37/02 ,  C07H21/04 ,  C07K16/16 ,  C12N5/10 ,  C12N15/74 ,  C12P21/00

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：MY147217A

公开(公告)日：2012-11-14

申请号：MYPI20081917

申请日：2006-12-04

Applicant: UCB PHARMA SA

Inventor： EVAN GELINAS RICHARD ,  CHOUDHURY SINGHAL MITRA ,  YI ZHANG ,  GEORGE POPPLEWELL ANDREW ,  RALPH ADAMS

IPC: C07K16/24

Abstract: THE INVENTION RELATES TO ANTIBODY MOLECULES HAVING SPECIFICITY FOR ANTIGENIC DETERMINANTS OF IL-6, THERAPEUTIC USES OF THE ANTIBODY MOLECULES AND METHODS FOR PRODUCING SAID ANTIBODY MOLECULES.

公开(公告)号：IS3016B

公开(公告)日：2019-10-15

申请号：IS8986

申请日：2011-11-18

Applicant: UCB PHARMA SA

Inventor： SINGH ATHWAL DILJEET ,  THOMAS BROWN DEREK ,  NEIL CHARLES WEIR ANDREW ,  GEORGE POPPLEWELL ANDREW ,  PAUL CHAPMAN ANDREW ,  JOHN KING DAVID

IPC: C12N15/09 ,  A61K39/395 ,  C12N15/13 ,  A61K47/48 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C07K16/46 ,  C07K19/00 ,  C12N1/21 ,  C12N15/62 ,  C12N15/70 ,  C12P21/02 ,  C12P21/08

公开(公告)号：PH12013500858A1

公开(公告)日：2016-01-25

申请号：PH12013500858

申请日：2013-04-29

Applicant: UCB PHARMA SA ,  BIOGEN MA INC

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  YEN-MING HSU ,  LIHE SU ,  TAYLOR FREDERICK R ,  RALPH ADAMS ,  THOMAS BROWN DEREK ,  GEORGE POPPLEWELL ANDREW ,  KIM ROBINSON MARTYN ,  ANTHONY SHOCK ,  LOUISE TYSON KERRY

IPC: A61K39/395 ,  C07K16/28 ,  C12N15/13 ,  C12N15/63

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.